Case Study
Enhancing Clinical Development Plan and Regulatory Support for Small Emerging Biopharma in Neuroma Therapy
Integrating IQVIA's market analysis and regulatory expertise to facilitate informed decision-making and streamlined interactions with the FDA.
Oct 24, 2024
Download

This case study explores how a small emerging biopharma (EBP) company engaged IQVIA to refine their clinical development plan for an existing drug targeting interdigital neuroma (foot neuroma).

IQVIA's extensive experience brought critical insights to meet the company's objectives. These included determining outcomes important to various stakeholders including payers, physicians and patients, conducting a market assessment, and preparing a Type C meeting request with FDA to align on regulatory requirements.

Learn how IQVIA's capabilities helped implement real-world and commercial insights into your clinical development planning to drive business growth.

Related solutions

Contact Us